These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 36444486)

  • 1. Fentanyl withdrawal: Understanding symptom severity and exploring the role of body mass index on withdrawal symptoms and clearance.
    Luba R; Jones J; Choi CJ; Comer S
    Addiction; 2023 Apr; 118(4):719-726. PubMed ID: 36444486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of Tramadol Extended-Release for Opioid Withdrawal: A Randomized Clinical Trial.
    Dunn KE; Tompkins DA; Bigelow GE; Strain EC
    JAMA Psychiatry; 2017 Sep; 74(9):885-893. PubMed ID: 28700791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A double blind, within subject comparison of spontaneous opioid withdrawal from buprenorphine versus morphine.
    Tompkins DA; Smith MT; Mintzer MZ; Campbell CM; Strain EC
    J Pharmacol Exp Ther; 2014 Feb; 348(2):217-26. PubMed ID: 24227768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sublingual dexmedetomidine (BXCL501) reduces opioid withdrawal symptoms: findings from a multi-site, phase 1b/2, randomized, double-blind, placebo-controlled trial.
    Jones JD; Rajachandran L; Yocca F; Risinger R; De Vivo M; Sabados J; Levin FR; Comer SD
    Am J Drug Alcohol Abuse; 2023 Jan; 49(1):109-122. PubMed ID: 36630319
    [No Abstract]   [Full Text] [Related]  

  • 5. Assessment of pioglitazone and proinflammatory cytokines during buprenorphine taper in patients with opioid use disorder.
    Schroeder JR; Phillips KA; Epstein DH; Jobes ML; Furnari MA; Kennedy AP; Heilig M; Preston KL
    Psychopharmacology (Berl); 2018 Oct; 235(10):2957-2966. PubMed ID: 30079432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preliminary evidence of different and clinically meaningful opioid withdrawal phenotypes.
    Dunn KE; Weerts EM; Huhn AS; Schroeder JR; Tompkins DA; Bigelow GE; Strain EC
    Addict Biol; 2020 Jan; 25(1):e12680. PubMed ID: 30295400
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differences in patient-reported and observer-rated opioid withdrawal symptom etiology, time course, and relationship to clinical outcome.
    Dunn K; Bergeria C; Huhn AS; Strain EC
    Drug Alcohol Depend; 2020 Oct; 215():108212. PubMed ID: 32781310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase III, randomized, multi-center, double blind, placebo controlled study of safety and efficacy of lofexidine for relief of symptoms in individuals undergoing inpatient opioid withdrawal.
    Gorodetzky CW; Walsh SL; Martin PR; Saxon AJ; Gullo KL; Biswas K
    Drug Alcohol Depend; 2017 Jul; 176():79-88. PubMed ID: 28527421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The relationship between pupil diameter and other measures of opioid withdrawal during naloxone precipitated withdrawal.
    Bergeria CL; Huhn AS; Tompkins DA; Bigelow GE; Strain EC; Dunn KE
    Drug Alcohol Depend; 2019 Sep; 202():111-114. PubMed ID: 31336328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Precipitated Opioid Withdrawal Treated With Ketamine in a Hospitalized Patient: A Case Report.
    Christian NJ; Butner JL; Evarts MS; Weimer MB
    J Addict Med; 2023 Jul-Aug 01; 17(4):488-490. PubMed ID: 37579118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose-dependent naloxone-induced morphine withdrawal symptoms in opioid-dependent males-a double-blinded, randomized study.
    Weisshaar S; Brandt L; Litschauer B; Sheik-Rezaei S; Moser L; Nirnberger G; Kühberger E; Bauer U; Firbas C; Gouya G; Wolzt M; Fischer G
    Br J Clin Pharmacol; 2020 Aug; 86(8):1610-1619. PubMed ID: 32145041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Psychometric evaluation of the 10-item Short Opiate Withdrawal Scale-Gossop (SOWS-Gossop) in patients undergoing opioid detoxification.
    Vernon MK; Reinders S; Mannix S; Gullo K; Gorodetzky CW; Clinch T
    Addict Behav; 2016 Sep; 60():109-16. PubMed ID: 27124502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Buprenorphine Weekly Depot (CAM2038) and Hydromorphone Blockade in Individuals With Opioid Use Disorder: A Randomized Clinical Trial.
    Walsh SL; Comer SD; Lofwall MR; Vince B; Levy-Cooperman N; Kelsh D; Coe MA; Jones JD; Nuzzo PA; Tiberg F; Sheldon B; Kim S
    JAMA Psychiatry; 2017 Sep; 74(9):894-902. PubMed ID: 28655025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patterns of withdrawal in patients with opioid use disorder (OUD) transitioning from untreated OUD or buprenorphine treatment to extended-release naltrexone.
    Mannelli P; Douaihy AB; Zavod A; Legedza A; Akerman SC; Sullivan MA
    Am J Drug Alcohol Abuse; 2021 Nov; 47(6):753-759. PubMed ID: 34752714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fentanyl exposure and preferences among individuals starting treatment for opioid use disorder.
    Gryczynski J; Nichols H; Schwartz RP; Mitchell SG; Hill P; Wireman K
    Drug Alcohol Depend; 2019 Nov; 204():107515. PubMed ID: 31525569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Challenges with buprenorphine inductions in the context of the fentanyl overdose crisis: A case series.
    Shearer D; Young S; Fairbairn N; Brar R
    Drug Alcohol Rev; 2022 Feb; 41(2):444-448. PubMed ID: 34647379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Naloxone-Induced Withdrawal in Individuals With and Without Fentanyl-Positive Urine Samples.
    Jones JD; Sherwin E; Martinez S; Comer SD
    Am J Addict; 2020 Jan; 29(1):51-56. PubMed ID: 31782591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conversion of chronic pain patients from full-opioid agonists to sublingual buprenorphine.
    Daitch J; Frey ME; Silver D; Mitnick C; Daitch D; Pergolizzi J
    Pain Physician; 2012 Jul; 15(3 Suppl):ES59-66. PubMed ID: 22786462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety, efficacy, and long-term results of a modified version of rapid opiate detoxification under general anaesthesia: a prospective study in methadone, heroin, codeine and morphine addicts.
    Hensel M; Kox WJ
    Acta Anaesthesiol Scand; 2000 Mar; 44(3):326-33. PubMed ID: 10714849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discrimination of a single dose of morphine followed by naltrexone: substitution of other agonists for morphine and other antagonists for naltrexone in a rat model of acute dependence.
    Holtzman SG
    J Pharmacol Exp Ther; 2003 Mar; 304(3):1033-41. PubMed ID: 12604679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.